Melinta Therapeutics Launches New Antibiotic Stewardship Program to Combat Growing Threat of Antimicrobial Resistance

Part of Strong Company Presence at 2018 MAD-ID Annual Meeting NEW HAVEN, Conn. , May 11, 2018 (GLOBE NEWSWIRE) — Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, today announced


Leave a Reply

Your email address will not be published.